Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Rodrigo-Claverol M, Malla-Clua B, Rodrigo-Claverol E, Jove-Naval J, Bergada-Bell-Iloc J, Marsal-Mora JR. Animal-assisted therapy for the emotional well-being of children with intellectual disabilities and behavioral disorders. Sociology and Anthropology. 2018 Jan;6(1):94-106. doi: 10.13189/sa.2018.060109
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Capdevila Bert R, Marsal Mora JR, Pujol Salud J, Anguera Farran R. Prevalence study of iodine deficiency in a 6-year-old school population. An Pediatr (Barc). 2010 May;72(5):331-8. doi: 10.1016/j.anpedi.2009.12.023
Willett W, Greenland S, MacMahon B, Trichopoulos D, Rothman KJ, Thomas D. The discipline of epidemiology. Science. 1995 Sep 8;269(5229):1325-6. doi: 10.1126/science.7660105
Rothman KJ. Journal policies on conflict of interest. Science. 1993 Sep 24;261(5129):1661. doi: 10.1126/science.8378766